Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation

Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called — omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.

Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (258 K)Download as PowerPoint slideHighlights► Recombinant therapeutic protein production is a multibillion dollar market. ► E. coli comprises 30% of recombinant protein production but not suitable for human therapeutics. ► Eukaryotic systems other than yeast are costly or not so efficient regarding protein yields. ► S. cerevisiae shows a high potential to be a suitable platform for therapeutic proteins. ► Human blood proteins are the next candidates to be challenged by S. cerevisiae system.